Reply:

References

1. 1.↵
   2. Vaneckova M,
   3. Herman M,
   4. Smith MP, et al

   . The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT study). AJNR Am J Neuroradiol 2015;36:1589–98 doi:10.3174/ajnr.A4468 pmid:26185325

   Abstract/FREE Full Text
2. 2.↵
   2. Colosimo C,
   3. Knopp MV,
   4. Barreau X, et al

   . A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumors. Neuroradiology 2004;46:655–65 pmid:15205859

   CrossRefPubMed
3. 3.↵
   2. Knopp MV,
   3. Runge VM,
   4. Essig M, et al

   . Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55–64 doi:10.1148/radiol.2301021085 pmid:14695387

   CrossRefPubMed
4. 4.↵
   2. Essig M,
   3. Tartaro A,
   4. Tartaglione T, et al

   . Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 2006;13:744–51 doi:10.1016/j.acra.2006.02.056 pmid:16679277

   CrossRefPubMed
5. 5.↵
   2. Rumboldt Z,
   3. Rowley HA,
   4. Steinberg F, et al

   . Multicenter, double-blind, randomised, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging 2009;29:760–67 doi:10.1002/jmri.21695 pmid:19306364

   CrossRefPubMed
6. 6.↵
   2. Maravilla KR,
   3. Maldjian JA,
   4. Schmalfuss IM, et al

   . Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389–400 doi:10.1148/radiol.2402051266 pmid:16801373

   CrossRefPubMed
7. 7.↵
   2. Kuhn MJ,
   3. Picozzi P,
   4. Maldjian JA, et al

   . Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557–66 doi:10.3171/jns.2007.106.4.557 pmid:17432704

   CrossRefPubMed
8. 8.↵
   2. Rowley HA,
   3. Scialfa G,
   4. Gao PY, et al

   . Contrast-enhanced MR imaging of brain lesions: a large scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684–91 doi:10.3174/ajnr.A1185 pmid:18599575

   Abstract/FREE Full Text
9. 9.↵
   2. Seidl Z,
   3. Vymazal J,
   4. Mechl M, et al

   . Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 2012;33:1050–58 doi:10.3174/ajnr.A3033 pmid:22383237

   Abstract/FREE Full Text
10. 10.↵
    2. Feinstein AR,
    3. Cicchetti DV

    . High agreement but low kappa, I: the problems of two paradoxes. J Clin Epidemiol 1990;43:543–49 doi:10.1016/0895-4356(90)90158-L pmid:2348207

    CrossRefPubMedWeb of Science
11. 11.↵
    MultiHance: Summary of Product Characteristics; last updated version December 4, 2015. Available at: https://www.medicines.org.uk/emc/medicine/6132. Accessed January 8, 2016.
12. 12.↵
    2. Staub LP,
    3. Lord SJ,
    4. Simes RJ, et al

    . Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Med Res Methodol 2012;12:12 doi:10.1186/1471-2288-12-12 pmid:22333319

    CrossRefPubMed